Volume 28, Supplement—December 2022
SUPPLEMENT ISSUE
Surveillance
Leveraging International Influenza Surveillance Systems and Programs during the COVID-19 Pandemic
, Margaret McCarron, William Davis, Ledor S. Igboh, Joshua A. Mott, Kathryn E. Lafond, Weigong Zhou, Marjorie Sorrells, Myrna D. Charles, Philip Gould, Carmen Sofia Arriola, Vic Veguilla, Erica Guthrie, Vivien G. Dugan, Rebecca Kondor, Eric Gogstad, Timothy M. Uyeki, Sonja J. Olsen, Gideon O. Emukule, Siddhartha Saha, Carolyn Greene, Joseph S. Bresee, John Barnes, David E. Wentworth, Alicia M. Fry, Daniel B. Jernigan, and Eduardo Azziz-Baumgartner
Table 2
Number of SARS-CoV-2 tests and median number of tests per 1,000 persons and per confirmed COVID-19 case among 64 CDC Influenza Division partner LMICs across 3 periods*
| Period | No. (%) | Cumulative no. tests† | Median no. tests/1,000 persons (IQR)† | Median no. tests/confirmed case (IQR)† |
|---|---|---|---|---|
| Jan–Jun 2020 | 41 (64) | 40,092,751 | 8.2 (3.6–24.6) | 20.9 (9.3–34.4) |
| Jan–Sep 2020 | 42 (66) | 158,319,895 | 28.4 (11.8–70.1) | 11.6 (6.8–24.2) |
| Jan 2020–Oct 2021 | 45 (70) | 1,051,798,691 | 240.7 (90.1–424.8) | 8.5 (5.7–14.0) |
*Partner countries were defined as LMICs that received CDC funding to support influenza surveillance activities since 2013. LMICs were included if they reported SARS-CoV-2 testing data on >13% of the days that they reported any COVID-19 data (e.g., confirmed cases and hospitalizations) to approximate 4-times-per-month (4/30 days) reporting. CDC, US Centers for Disease Control and Prevention; IQR, interquartile range; LMICs, low- and middle-income countries. †Testing data were extracted from ministry of health and other government webpages, and included either reverse transcription PCR tests, antigen tests, or both.